Preclinical development of molecular-targeted agents for cancer
Molecular-targeted agents are increasingly used for the treatment of cancer. However, the
attrition rate for drugs that enter early clinical trials is higher than for other branches of …
attrition rate for drugs that enter early clinical trials is higher than for other branches of …
Preclinical development of molecular-targeted agents for cancer
A Ocana, A Pandiella, LL Siu… - Nature reviews …, 2010 - pubmed.ncbi.nlm.nih.gov
Molecular-targeted agents are increasingly used for the treatment of cancer. However, the
attrition rate for drugs that enter early clinical trials is higher than for other branches of …
attrition rate for drugs that enter early clinical trials is higher than for other branches of …
Preclinical development of molecular-targeted agents for cancer.
A Ocana, A Pandiella, LL Siu… - Nature reviews. Clinical …, 2010 - europepmc.org
Molecular-targeted agents are increasingly used for the treatment of cancer. However, the
attrition rate for drugs that enter early clinical trials is higher than for other branches of …
attrition rate for drugs that enter early clinical trials is higher than for other branches of …
[PDF][PDF] Preclinical development of molecular-targeted agents for cancer
A Ocana, A Pandiella, LL Siu… - NATURE REVIEWS …, 2011 - researchgate.net
Molecular-targeted agents are increasingly used for the treatment of cancer. However, the
attrition rate for drugs that enter early clinical trials is higher than for other branches of …
attrition rate for drugs that enter early clinical trials is higher than for other branches of …
Preclinical development of molecular-targeted agents for cancer
A Ocaña, A Pandiella - 2011 - digital.csic.es
Molecular-targeted agents are increasingly used for the treatment of cancer. However, the
attrition rate for drugs that enter early clinical trials is higher than for other branches of …
attrition rate for drugs that enter early clinical trials is higher than for other branches of …
Preclinical development of molecular-targeted agents for cancer
A Ocana, A Pandiella, LL Siu… - Nature Reviews Clinical …, 2011 - go.gale.com
Molecular-targeted agents are increasingly used for the treatment of cancer. However, the
attrition rate for drugs that enter early clinical trials is higher than for other branches of …
attrition rate for drugs that enter early clinical trials is higher than for other branches of …
Preclinical development of molecular-targeted agents for cancer
A Ocana, A Pandiella, LL Siu… - Nature Reviews. Clinical …, 2010 - hero.epa.gov
Molecular-targeted agents are increasingly used for the treatment of cancer. However, the
attrition rate for drugs that enter early clinical trials is higher than for other branches of …
attrition rate for drugs that enter early clinical trials is higher than for other branches of …
[引用][C] Preclinical development of molecular-targeted agents for cancer
A Ocana, A Pandiella, LL Siu, IF Tannock - Nature Reviews Clinical …, 2010 - cir.nii.ac.jp
Preclinical development of molecular-targeted agents for cancer | CiNii Research CiNii 国立
情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす …
情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす …